Clore Laboratory
Diabetes, Obesity and Metabolic Research

This internationally recognised research group has interests in molecular genetics, biochemistry, pharmacology, nutrition and the physiology of metabolic diseases, particularly diabetes and obesity.

The Clore Laboratory is led by Professors Mike Cawthorne and Jon Arch, researchers with a track record in drug discovery, including β₃-adrenoceptor agonists and the thiazolidinedione insulin sensitiser rosiglitazone.

Strategic alliance with GW Pharmaceuticals on cannabinoids for metabolic disease
GW Pharmaceuticals plc has entered into an exclusive strategic alliance with the Clore Laboratory, University of Buckingham focusing on the research of cannabinoids and other phytomedicines in the field of type 2 diabetes and metabolic disease.

Nobel Laureate Sir Martin Evans gives seminar in Clore Laboratory
Prior to receiving an Honorary Degree from the University of Buckingham on 27 February 2009, Sir Martin Evans gave a seminar in the Clore Laboratory entitled 'The origin of embryonic stem cells'.

Mike Cawthorne proposes radical rethink of diabetes treatment
Professor Cawthorne gave a talk entitled 'Glitazones revisited' to diabetes healthcare professionals at the 10th National Diabetes Conference

Scholarship fund established in memory of Monique Heald
A scholarship fund for research students in science is seeking donations.

Contract Research Services expanded
Hyperlipidemic model added to metabolic disease model portfolio.

Other News

Job Opportunities